Who is sponsoring NCT03615755?

NCT03615755 is sponsored by Hendry Irawan.

What drugs are being tested in NCT03615755?

Interventions in NCT03615755: Hyperbaric Oxygen Therapy (HBOT).

What condition does NCT03615755 study?

NCT03615755 studies Hyperbaric Oxygen Therapy, Diabetic Foot Ulcer, Type II Diabetes Mellitus.

Is NCT03615755 still recruiting?

NCT03615755 is currently completed. Last updated 4 May 2020.

Last reviewed 2020-05-04 · How we verify

NCT03615755

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine

Completed NA Last updated 4 May 2020

What this trial tests

NA trial testing Hyperbaric Oxygen Therapy (HBOT) in Hyperbaric Oxygen Therapy in 30 participants. Completed in 31 March 2017.

Timeline

27 December 2016

Primary endpoint
31 March 2017

31 March 2017

Quick facts

Lead sponsor	Hendry Irawan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	30
Start date	27 December 2016
Primary completion	31 March 2017
Estimated completion	31 March 2017

Drugs / interventions tested

Hyperbaric Oxygen Therapy (HBOT)

Conditions studied

Hyperbaric Oxygen Therapy — all drugs for Hyperbaric Oxygen Therapy →
Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →
Type II Diabetes Mellitus — all drugs for Type II Diabetes Mellitus →

Sponsor

Hendry Irawan

Who can join

18 and older, any sex, with Hyperbaric Oxygen Therapy or Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators want to evaluate the short duration HBOT can improve glycohemoglobin (HbA1c) levels, leukocyte count, and serum creatinine levels in patients with DFU (diabetic foot ulcer) Wagner 3-4.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Pilot Study of Short-Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine in Patients with Diabetic Foot Ulcer Wagner 3-4.
Irawan H, Semadi IN, Widiana IGR. · · 2018 · cited 16× · PMID 30158840 · DOI 10.1155/2018/6425857

Verify or expand the search:

Other trials of Hyperbaric Oxygen Therapy (HBOT)

Trials testing the same drug.

NCT04619719 — Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia · NA · terminated
NCT07091266 — SNM vs. HBOT for Refractory IC/BPS · NA · completed
NCT07422168 — Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications · NA · completed

Other recruiting trials for Hyperbaric Oxygen Therapy

Currently open trials in the same condition.

NCT03144206 — Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03615755 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hendry Irawan
Last refreshed: 4 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03615755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing